Roth Capital Says IMAX Should Be Bought On Weakness
By Benzinga Staff
November 05, 2009 9:30 AM
November 05, 2009 9:30 AM
IMAX Corporation (Nasdaq: IMAX) is up 5% this morning after Roth Capital said investors should look at buying IMAX on weakness. Roth does have a Buy rating on IMAX.
After Cinemark (NYSE: CNK) filed a lawsuit against IMAX in an attempt to invalidate two of its patents, Roth believes that investors need to realize that it only focus on two of IMAX's 90+ patents.
Roth Capital questions the validity of Cinemark's claims since IMAX has been providing large-format movies for a much longer period of time.
(c) 2011 Benzinga.com. All rights reserved. This material may not be published in its entirety or redistributed without the approval of Benzinga.
We're Loving
